长春西汀纳米结构脂质载体的研究

《长春西汀纳米结构脂质载体的研究》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、单位代码：10222学号：09843029分类号：佳木斯大学硕士学位论文论文题目：长春西汀纳米结构脂质载体的研究研究生姓名：赵昱学科、专业：药剂学导师姓名、职称：杨春荣副教授论文答辩日期：2012年6月2日佳木斯大学硕士学位论文佳木斯大学硕士学位论文论文题目：长春西汀纳米结构脂质载体的研究研究生：赵昱专业：药剂学指导教师：杨春荣单位：佳木斯大学协助指导教师：单位：单位：单位：学习期限：2009年9月至2012年7月学位授予单位：佳木斯大学佳木斯大学硕士学位论文学术诚信承诺本人郑重声明：所呈交的论文是我个人

2、在导师指导下进行的研究工作及取得研究成果。尽我所知，除了文中特别加以标注和致谢的地方外，论文中不包含其他人已经发表或撰写的研究成果，也不包含为获得佳木斯大学或其他教育机构的学位或证书所使用过的材料。与我一同工作的同志对本研究所做的任何贡献均已在论文中做了明确的说明并表示了谢意。签名：___________日期：____________关于论文使用授权的说明本人完全了解佳木斯大学有关保留、使用学位论文的规定，即：学校有权保留送交论文的复印件，允许论文被查阅和借阅；学校可以公布论文的全部或部分内容，可以采用影

3、印、缩印或其他复制手段保存论文。（保密的论文在解密后应遵循此规定）签名：___________导师签名：___________日期：____________佳木斯大学硕士学位论文目录摘要···········································································································ⅤAbstract··············································

4、·························································Ⅵ前言···········································································································1第一章文献综述················································································

5、···········21.1老年痴呆病的概述·················································································21.2长春西汀的简介····················································································21.2.1药理作用··············································

6、·········································31.2.2药动学研究····················································································41.2.3毒理作用·······················································································41.2.4临床应用············

7、···········································································51.3血脑屏障的研究现状·············································································51.4纳米结构脂质载体的简介·······································································51.4

8、.1纳米结构脂质载体常用制备方法·························································61.4.2NLC制剂特点················································································71.4.3NLC给药途径的研究·································